Beckman Coulter and Arkray announce the partnership and launch of the iQ Workcell

Beckman Coulter and U.S. Arkray, Inc. have entered into a new partnership and have launched the iQ Urinalysis Workcell. The iQ Workcell pairs two of the world’s most highly regarded automated urine analyzers, the Beckman Coulter Iris iQ200 digital flow morphology system and the Arkray Aution Max AX-4030 fully automated urine analyzer. This total urinalysis offering will be available in the United States of America exclusively through Beckman Coulter. Beckman Coulter will also offer both the Arkray Aution Max AX-4030 and the Arkray Aution Eleven AE-4022 analyzers as stand-alone solutions, reinforcing Beckman Coulter’s commitment to offering scalable solutions for high-, mid-, and low-volume laboratory needs. This partnership will allow both companies to better meet the needs of their growing customer bases. Arkray has a long-standing history with over 40 years of experience in urine chemistry and is a pioneer of diagnostic products. Arkray’s reliable urine chemistry analyzers and test strips provide one of the broadest reporting ranges. The expanded ranges will allow US customers to report additional clinically relevant data.

Further, harmonized urine chemistry strips across the semi-automated and fully automated Aution products offer an excellent complement to the powerful auto-particle recognition on Beckman Coulter’s iQ platform. The new iQ Workcell is a scalable solution that will be offered in three configurations – iQ 3000, 2000, and 1500 Workcells – to meet laboratories’ workflow needs. Beckman Coulter’s proprietary digital flow morphology process auto-classifies 12 particle types with 27 sub-categories and reduces subjectivity during data analysis. The Arkray urine chemistry strips have broad measuring ranges for expanded clinical utility. The Arkray Aution Eleven AE-4022 semi-automated urine chemistry analyzer is an ideal backup or stand-alone option for laboratories as urine chemistry results are harmonized across all platforms within the partnership’s portfolio.